mProX™ Human CD274 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD274, also known as PD-L1, has various applications in cancer research and treatment. In gastric cancer, CD274 is part of a prognostic model that predicts patient outcomes and survival. High expression of CD274 is associated with a less favorable outcome in gastric cancer patients. CD274 is also linked to immune checkpoints and immune cells, suggesting its potential role in immunotherapeutic strategies. In metastatic urothelial carcinoma, CD274 promoter hypomethylation is a predictive biomarker for response to immune checkpoint blockade therapy. PD-L1 positivity, determined by CD274 expression, is associated with longer progression-free survival and overall survival in certain subtypes of non-small cell lung cancer (NSCLC) with EGFR mutations. CD274-induced senescence in breast cancer cells has enhanced anti-tumor immunogenic properties compared to DNA-damaging agents. Additionally, CD274 expression is used to assess the efficacy and safety of pembrolizumab, an immunotherapy, in the first-line treatment of metastatic lung cancer. Real-world data confirms the efficacy and safety of pembrolizumab in lung cancer treatment. Overall, CD274 plays a crucial role in tumor immune microenvironment analysis, immunotherapy response prediction, and treatment outcomes in various cancers.